Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is alot of restrictions on converting PRC currency to foriegn currency...mentioned on pages 20, 21 in the 10K.
Also there is a statement in mid-page 22, about it being UNlikely to pay cash divys in the forseeable future.
I don't believe anyone outside of Chinese nationals can be paid dividends/EPS.
no problem....I did get a little excited though! I figure we'll get there by 2016 or so.
Ah, I see your point Factor of 10 out. Sorry for the confusion.
rich
I just saw the presentation. The projected EPS numbers are 2011-$.052 and 2012-$.07
Nimbex Off patent in 2012?
What I saw it was 2012 [1] whereas the research report [2] said 2012. Since it's a mid-term aim to go international with Cisatracurium Besylate I'm thinking it's 2012.
rich
[1] http://www.locumusa.com/pdf/members/ij_dop_0200.pdf
[2] http://www.harbingerresearch.com/data/Harbinger%20Research%20SNBP%20Report%20July%207%202010_718.pdf
Here's the presentation.... I think it must create unique ID when you download it - didn't realise no-one else could see. So here's the link and you can open it and check for yourself.
http://ir.stockpr.com/sinobiopharma/presentations
rich
Gorilla...I haven't seen the presentation....but is this number really correct?
"EPS for 2011 added (excluding non-cash charges) 0.52 2012 $0.70"
September Presentation & Changes from April Presentation
Investment highlights – emphasises FY11 $14M Rev $6M Net (old pres no FY11 estimate)
Increase Sales of KuTai from 10M to 12M
Expected Sales of YiTai down to $2M from $4M
Commercial 2 – Pipeline 5
Four Marketed Products and five major new products in pipeline (prev 6 - diapeptide has been removed)
High Margin Business Model up from >65% to >70%
EPS for 2011 added (excluding non-cash charges) 0.52 2012 $0.70
My comment
Disappointing to see YiTai estimates down but not shocked as any new drug takes time to be accepted.
KuTai from $10M to $12 M seems plausible since that PR suggesting distributors wanted $10M
Ahem,somewhat convenient to keep total revenue estimates the same .
Nothing unusual in some pipeline products disappearing
Nice to see EPS rather than net income.
Not been following company long so any comment from long-timer welcome.
rich
OLD Presentation
http://www.sec.gov/Archives/edgar/data/1403612/000114036110027779/sinob_ex99-1.htm
New Presentation
http://content.stockpr.com/sinobiopharma/media/71bb6e0848d923f71e306cb5c427e580.pdf
rich
With 1st qtr numbers in a couple weeks this looks like a good time to buy some shares.
2010 bottomline went from -$0.03 to +$0.03 almost entirely from their flagship product that should see its astounding growth continue for 3 more years.
They have more drugs in development that could become World class products in there category.
At least one new drug should add to 1st qtr results & I will be glad to see snbp become more than a one drug pony even if that one drug has further growth ahead as it becomes a worlwide leading drug of choice.
So - let me get this straight in my head.
It looks like profits and margins increased this time around, some debt has been delt with, and revenues appear to be increasing,...
And yet the share price drops again? Figures.
SNBP filed after the market closed. 2010 eps $0.03 vs-$0.03 in 2009 meeting management guidance.
Revenue doubled almost entirely from their flagship product.
margin improvement due to increased revenue from the flagship product helped the bottomline while increased sharecount did not.
However some debt was extingished & the balance sheet showed marked improvement.
It will be interesting to see how much newer products contribute to revenue in the upcoming 1st qtr 2011 results ending August 31.
They still have a strong pipeline of products in development that need additional funding.
"The dilution worries me and this bs late reporting in this nasty market is plain inexcusable."
You have mentioned two good reasons for selling this stock & I am glad you didn't lose money by selling.
As long as the eps & shareholder equity continue to grow at a fast pace in spite the added shares I will hold my shares.
They did report late last year as well. So while this is not something I like to see from a stock I hold. Its nothing new.
Much of being a successful company is having a strong highly qualified management team to guide & deliver results.
That is the main reason I made this my largest position,,,even bigger than hfgb & ckgt my next two biggest positions.
If management fails to deliver the bottomline growth I am expecting going forward or the pps hits my target I will sell.
If they fail to report by Sept 15th as I expect with excellant results I might sell.
Good luck with your remaining stocks in this harsh current market.
I believe China stocks will again return to favor before yearend.
While I share your enthusiasm re HFGB and continue to patiently hold CKGT for anticipatedLT gains, I dumped SNBP last month and consider myself lucky to have broken even.
The dillution worries me and this bs late reporting in this nasty market is plain inexcusable.
Best of luck to you on all your picks as always.
Looks like we may not see earnings until around the 15th Sept. the date they reported last year.
This delay sure isn't helping the current pps.
However I expect that they will meet or beat their own projected eps of $0.03 for 2010.
And with many new drugs coming to market 2011 should be a very strong year of growth.
I would like to see two things change in 2011.
1] Slower increase in shares outstanding.
2] Start reporting on time.
Those two changes would not only increase bottom-line eps to at least $0.07 in 2011 but should also get the pps over a buck.
Once over a buck a reverse split to facilitate listing could bring in the capitol needs to finance future growth with far less future dilution.
Enough rambling for today...pappy,,,out.
SNBP – Same deal as many of the others, a nice little consolidation range that’s forming on top of the previous channel. Thanks to a very tight trading range, we now have a clear cut trigger point at .29, aka the recent consolidation’s high point.
http://flippingpennystocks.com/?p=671
? .251?...what a poor move by a whacker....fool. (If your going to "Whack", why so low?) 11%+ below bid is just dumb.
Pfitzer has had some trials for eplerenone, and the benifits were so remarkable, cancelled further enrollment. Intrem findings had shown huge percentage of patients recieving the drug Vs placebo had improvements. (Eplerenone is safer, cleaner than Spironolactone used in similar therapys.)
http://www.theheart.org/article/1083009.do
Good News Out Today!
Press Release Source: Sinobiopharma, Inc. On Tuesday August 10, 2010, 9:14 am EDT
NANTONG CITY, China, Aug. 10, 2010 (GLOBE NEWSWIRE) -- Sinobiopharma, Inc. (OTCBB:SNBP - News) ("Sinobiopharma" or the "Company"), an innovative biopharmaceutical products company with primary operations in China, today announced that the Company, through its wholly-owned subsidiary Dong Ying (Jiangsu) Pharmaceutical Co., Ltd., has signed an agreement with Jiangsu Lianhuan Pharmaceuticals Co., Ltd. ("Lianhuan") to co-develop, manufacture and commercialize Eplerenone, a therapeutic agent formulated to treat high blood pressure and vascular diseases. Sinobiopharma is the first Chinese pharmaceutical company that received the approval from the Chinese State FDA for clinical trial of Eplerenone in China. If successfully commercialized, the Company anticipates that Eplerenone will enjoy multi-year market exclusivity based on its first-to-market status.
Under the terms of the agreement, upon successful launch of the product, Sinobiopharma will receive 60% of Eplerenone's profits while Lianhuan is entitled to the balance. Sinobiopharma has received authorization from the China State Food and Drug Administration (SFDA) to commence clinical trials. Lianhuan has agreed to execute and fund the cost of clinical development, regulatory applications and manufacturing of Eplerenone. The companies intend to jointly market Eplerenone based on their different geographical strengths in China.
"We are pleased to collaborate with a high quality, strong partner like Jiangsu Lianhuan," said Dr. Lequn Lee Huang, Chairman and Chief Executive Officer of Sinobiopharma. "We are highly optimistic about Eplerenone and believe that it could be an important growth driver, thanks to our first mover advantage with this compound and high technical barrier which would limit potential competition."
About Eplerenone
Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is specifically used for reducing cardiovascular risk in patients following myocardial infarction.
About Jiangsu Lianhuan Pharmaceuticals Co., Ltd.:
Lianhuan is a China-listed pharmaceutical company located in the Yangzhou, Jiangsu province of China. Lianhuan was established in 1958 and employs 1100 people. The company has GMP certified production lines, a strong research and development capability and occupies 190,000 square meters. For more information, visit: http://www.lhpharma.com/english/default.htm
About Sinobiopharma, Inc.
Sinobiopharma is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical markets. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd., Sinobiopharma's wholly-owned subsidiary in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. Sinobiopharma has patented new methods for synthesizing active pharmaceutical ingredients (API) at a lower cost and owns drug delivery formulations that improve usability. For additional information, please visit the Company's website at: www.sinobp.com.
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.
Contact:
Sinobiopharma, Inc.
James Mu, CFO
86-25-5806-1579
xjmu@sinobiopharma.com
Volume boost in last few minutes. (44,000 in a short timeframe.)
I highlighted the range this has been trading in for the past five months, and the dark green range is the consolidation that’s been taking place the past few weeks right near the ceiling of the channel. .28 is the trigger point I’m watching, which it’s temporarily busted through a couple times already, but so far it hasn’t stuck. Great looking breakout setup in progress.
http://flippingpennystocks.com/?page_id=444
Could it be the USA distributions are related to a deal? Just throwin' that out there, 'cause I haven't heard anything involving GSK/SNBP. GLTY.
"Someone posted that a deal with GSK would happen soon on the yahoo board."
I have seen no factual bases to verify the above statement.
However since GSK's "nimbex injection" cost much more than SNBP's "KuTai" & can't be stored at room temp. making it less desirable for doctors & hospitals to use.
The above speculation would present a interesting way for SNBP's KuTai to gain a foot hold into the U.S. market at a time when GSK would be losing revenue due to their product losing patent protection.
Good article. I hadn't seen that report before, but I based my opinion on most of the basics covered there.
I really believe that the company will succeed based on china's own demand for pharmacuticles. USA distributions tho' are key/springboard to a uplisting. (I don't exspect this anytime soon, but watch the product pipeline grow.) GL Pappy.
Anyone thinking of exit, would be a mistake at this time..JMO.
If you feel you must, please no bidwhacking. GLTA.
I've been in this for long term for a while. When it was more liquid I had flipped many times leading up to the .90's.
IMO, the company is in its best and most stabile position its ever been. Getting a strong base of distributions in the USA is key to spur PPS increases in the .50-.80's.
To do that, the company needs to overcome the perception that chinese MFG's sell tainted products. I'm drafting some reccommendations, to forward to the official site/web site
It is unfortunate that a few unscrupuless individuals let unsafe products reach consumers...this has created the perception that it is commonplace to do so.GLTY.
SNBP was my only loser Friday as Chinese stocks in general rallied off a very oversold pps.
SNBP had been very strong before most other China stocks & it seems has decided to consolidate some ahead of a earnings report that will probably beat companies $0.03 estimate for this year by a penny.imo
Its the longterm potential here that holds my interest as many strong new products are starting to enter the revenue stream.
A strong earnings report coupled with a update on new products release could push the pps to $0.50.imo
Co-marketing with Xianfeng, a privately-owned pharmacuetical company, financial details not yet released...Xianfeng gets access to the certs and formulas, SNBP gets reduced costs-of-manufactoring.(And new avenues of Distribution?)
http://www.stockmarketsreview.com/news/23193/
'Bout every 1/2 hr someones taking it down on puny volume....If ppl don't buy at the ask....(Need more news about USA distribution)
New corporate website, link below,
http://www.sinobp.com/
That would not hurt my feelings.
Closed up @ .27, gain of 12.5% for the day, up 35% from last week.
Out on a limb, I'd say with the recent pincer,(MACD 12 'n ADX 14) that next week would see the .30's (WAG, up to .32-.37)
When actual #'s come from the distribution contracts, we can have a real run. The flagship product, (Muscle-relaxer) is a proven compound...safe and effective, widely used all over the world. AND...SNBP's product doesn't require refridgeration due to it being freeze-dried, not liquid.
A bit surprised how little action theres been, but the $0.26 is encouraging. Some volume here would help.
12 month target $0.65
http://www.harbingerresearch.com/link/13/255/SNBP
"looks like junk to me"
Everyone has their own opinion.
Speculative yes but not junk.
This company has the best flagship product in its space & has many promising drugs approved or waiting approval.
Management is very well versed in developing & marketing new drugs.
Growth in recent qtrs has accelerated with eps growth expected to show about 50% growth over the next few years in spite a large increase in shares outstanding & cashflow + shareholder equity is also growing rapidly.
If share count starts to increase without a worh while increase in eps & shareholder equity then I would agree with your opinion.
To date that has not been the case.
looks like junk to me
Yep pappy - so I read.
Wish I had some cash on hand ready to spend to about double my holdings. But am cash poor for the next month or so.
Alas. But it's all good.
Company just announced $8.4m in distribution contracts for their flagship product in the 1st calender qtr of 2010.
pipeline;
http://www.sinobp.com/products/products-pending-approval
Cool - looks good. So why hasn't this stock caught on?
Not that I am going to object to it staying down a while longer so I can accumulate some more.
From todays power point presentation;
2009 R3.8M Net0.76M
2010E R7.7M N3.5M
2011E R13.6M N6.1M
2012E R21M N9.4M
wait for .01 and get in then.
Hmmm... thank you for your post - the thing that stopped me buying into it was the dilution - as discussed this commentary. Obviously, this is something you've considered.
http://chinaotcplayer.blogspot.com/2010/01/spotlight-behind-sinobiopharmas-stellar.html
I can see that having additional drugs is good and I like the fact that the drug they are selling is used in Western Medicine.
I guess it's how much you trust the management to build EPS rather than diluting. Have you contacted them? In the end you accept that this is a gamble with a high payout if it goes right?
rich
Rats! This really looked like a good one. Then I read in the 10-Q that they did a 50-1 split to increase their authorized shares to 2.5 BILLION! So even though outstanding shares is commedably low, there's a TON of room to dilute. What other reason to have such a high AS count. Am I off-base here? Opinions appreciated. Thanks.
I believe most bb stocks are a crapshoot.
In the case of snbp the balance sheet is improving rapidly while the pps has made a serious drop due to a large increase in sharecount that has also increased the float.
Even @ the current pps which is about 3x 2011 projected eps or less the pps is having trouble stabilizing.
However as many new drugs start to make their appearance onto the scene snbp will no longer be a 1 product company.
I base my opinion about the future of this company on a experienced managemt team that has the background & know how to deliver many new drugs in the immediate future while continuing to expand on their flagship product that has the potential to go global since it only costs a fraction of a simular U.S. product that is about to lose patent protection.
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
400
|
Created
|
09/26/08
|
Type
|
Free
|
Moderators |
117,587,608 as of 01/20/2011 (By Quotemedia) ......an increase of 17.6 million(Approx) from split for compensation for itellectual-propertys and services.
After a distinguished 20-year medical career in the U.S. that saw him become the Principal Scientist at Bayer's Pharmaceutical Division Research Centre in New Haven, CT, Dr. Lequn Huang returned to his native China to become founding Chair of Dong Ying Pharmaceutical Co. Ltd. in 2004.
He proceeded to recruit R&D and management teams to accelerate the growth of Dong Ying into a premier developer and manufacturer of innovative pharmaceuticals for the Chinese domestic and international markets.
Headquarters and a 30,000 sq. meter SFDA GMP-certified production facilities are located in the Nantong Economic and Technology Development Zone, which qualifies Sinobiopharma for extensive tax benefits. R&D labs are located in Nanjing, a major R&D centre with several universities and research institutes. A nationwide distribution network enables Sinobiopharma to market its products in every major city in China.
Dr. Lee Huang, "The market has shown a strong need for our flagship product, KuTai-(cisatracurium b.)
and the sales increases from this product are expected to continue for the next 2 years."
These upgrade were done to facilitate the expected increases in orders, and to provide economies of
scale. Production of cisatracurium besylate at the Dongying facility was uninterupted.
Current output could be doubled at anytime without the need for additional expenditures for new equiptment.
Financial highlights include:
2010 fiscal year
Sales revenue increased to $1,902,376 for the six months ended November 30, 2008 from $583,748 in the corresponding period in 2007.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |